Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Newcelx Ltd (NCEL)

Newcelx Ltd (NCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,581
  • Shares Outstanding, K 4,558
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,980 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +19.00%
on 01/13/26
3.25 -19.07%
on 02/10/26
+0.14 (+5.62%)
since 01/12/26
3-Month
1.89 +39.15%
on 12/31/25
4.70 -44.04%
on 12/10/25
-1.05 (-28.53%)
since 11/12/25
52-Week
1.89 +39.15%
on 12/31/25
30.80 -91.46%
on 06/30/25
-20.77 (-88.76%)
since 02/12/25

Most Recent Stories

More News
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset

NCEL : 2.76 (unch)
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership team

NCEL : 2.76 (unch)
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

ZURICH , Jan. 12, 2026 /PRNewswire/ --  NewcelX Ltd . (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported...

NCEL : 2.76 (unch)
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

ZURICH and NESS ZIONA, Israel , Jan. 5, 2026 /PRNewswire/ --  NewcelX Ltd . (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative...

NCEL : 2.76 (unch)
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseases

NCEL : 2.76 (unch)
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

ZURICH and NESS ZIONA, Israel , Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd . (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule...

NCEL : 2.76 (unch)
NLSP : 7.6200 (+2.97%)
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

ZURICH , Nov. 6, 2025 /PRNewswire/ --  NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for neurodegenerative and metabolic...

NCEL : 2.76 (unch)
NewcelX CEO Issues Letter to Shareholders

ZURICH , Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd . (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and...

NCEL : 2.76 (unch)
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.

ZURICH , Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies...

NCEL : 2.76 (unch)
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"

NLSPW : 0.0179 (-3.24%)
NLS : 0.8204 (+11.20%)
NCEL : 2.76 (unch)
NLSP : 7.6200 (+2.97%)

Business Summary

NewcelX is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. NewcelX, formerly known as NLS Pharmaceutics Ltd., is based in NESS ZIONA, Israel.

See More

Key Turning Points

3rd Resistance Point 3.21
2nd Resistance Point 3.12
1st Resistance Point 2.94
Last Price 2.76
1st Support Level 2.67
2nd Support Level 2.58
3rd Support Level 2.40

See More

52-Week High 30.80
Fibonacci 61.8% 19.76
Fibonacci 50% 16.34
Fibonacci 38.2% 12.93
Last Price 2.76
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar